Latest SEC filings for Johnson & Johnson (JNJ) explained in plain English: insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). Sourced directly from SEC EDGAR.
JOHNSON & JOHNSON filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.
JOHNSON & JOHNSON filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
HEWSON MARILLYN A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Pinto Daniel E (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Woods Eugene A. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Decker Robert J, listed as VP Corporate Controller at JOHNSON & JOHNSON, reported an open-market sale of 4,075 JNJ shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Decker Robert J filed a Form 144 with the SEC indicating intent to sell JNJ (JOHNSON & JOHNSON) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Schmid Timothy, listed as EVP, WW Chair, MedTech at JOHNSON & JOHNSON, reported an open-market sale of 1,322 JNJ shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Schmid Timothy filed a Form 144 with the SEC indicating intent to sell JNJ (JOHNSON & JOHNSON) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Swanson James D., listed as EVP, CIO at JOHNSON & JOHNSON, reported an open-market sale of 62,080 JNJ shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Wengel Kathryn E (EVP, Chief TO and Risk Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Mulholland Kristen (EVP, Chief HR Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Wolk Joseph J, listed as Exec VP, CFO at JOHNSON & JOHNSON, reported an open-market sale of 89,654 JNJ shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Decker Robert J (VP Corporate Controller) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
REED JOHN C, listed as EVP, Innovative Medicine, R&D at JOHNSON & JOHNSON, reported an open-market sale of 53,931 JNJ shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.